SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc.
NNVC 1.090-1.8%Dec 3 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: donpat who wrote (10487)6/14/2018 8:23:26 PM
From: HardToFind  Read Replies (1) of 12873
 
They've [Glaxo has] just gotta have NNVC in their sights.
I just don't think NNVC has finished making the business case for their product(s):
  1. Can we make them in commercial quantities, and how much will it cost to make them?
  2. Can we show safety & efficacy in humans, and then get drugs through FDA approval?
In my opinion, nobody at big pharma is going to reach for his or her "buyout" wallet until NNVC can answer those two questions to his or her satisfaction...and they cannot yet do that.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News